Although ghrelin was initially recognized for its role in feeding and metabolism, and consequently most expectations were pinned on its potential to treat obesity, the evidence to date, from rodent models of obesity, as well as human trials, suggests that antagonism of ghrelin signaling has only modest anti-obesity effects. Here, GHRL is linked to obesity disorder.